Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 8 for:    gattex | 1 years

Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02682381
Recruitment Status : Completed
First Posted : February 15, 2016
Results First Posted : October 16, 2018
Last Update Posted : May 16, 2019
Sponsor:
Information provided by (Responsible Party):
Shire

Brief Summary:
Teduglutide is approved for treatment of adults with short bowel syndrome (SBS). The purpose of this study is to evaluate the safety and efficacy of teduglutide in children up to the age of 17 with SBS who are dependent on parenteral support. Subjects may choose whether to receive the study drug or to participate in a standard-of-care arm. All participants who complete the study may be eligible to receive the study drug in a long-term extension study.

Condition or disease Intervention/treatment Phase
Short Bowel Syndrome Drug: Teduglutide 0.05mg/kg Drug: Teduglutide 0.025 mg/kg Other: Standard of Care Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 59 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Actual Study Start Date : June 23, 2016
Actual Primary Completion Date : August 18, 2017
Actual Study Completion Date : August 18, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Teduglutide

Arm Intervention/treatment
Experimental: 0.025 mg/kg/day Teduglutide
0.025 milligrams per kilogram per day (mg/kg/day) of teduglutide for 24 weeks.
Drug: Teduglutide 0.025 mg/kg
0.025 mg/kg

Experimental: 0.05 mg/kg/day Teduglutide
0.05 mg/kg/day of teduglutide for 24 weeks.
Drug: Teduglutide 0.05mg/kg
0.05 mg/kg

Active Comparator: Standard of care
Observational cohort for the 24-week treatment period and 4 week follow-up. The subjects in the standard of care group will follow the same visit schedule as the randomized subjects.
Other: Standard of Care
Observational cohort for the 24-week treatment period and 4 week follow-up.




Primary Outcome Measures :
  1. Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24 [ Time Frame: Baseline through Week 24 ]
    Reduction in weight-normalized PN/IV volume was performed using both participant diary and investigator prescribed data. Number of participants who achieved at least a 20% reduction in weight-normalized PN/IV volume between the baseline and week 24/EOT visit were reported.


Secondary Outcome Measures :
  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) [ Time Frame: From start of study treatment up to 28 weeks ]
    An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs that started or worsened on or after the date of first dose for treatment groups and those that started or worsened on or after the baseline visit for standard of care group.

  2. Number of Participants Who Were Completely Weaned Off Parenteral Nutrition Intravenous (PN/IV) Support at Week 24 [ Time Frame: Week 24 ]
    A participant was considered to have achieved independence from PN/IV support (completely weaned off PN/IV) if the investigator prescribed no PN/IV at EOT and there was no use of PN/IV recorded in the participant diary during the week prior to EOT.

  3. Change From Baseline in Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24 [ Time Frame: Baseline, Week 24 ]
    Change in PN/IV volume was reported based on the participant diary and the investigator prescribed data.

  4. Change From Baseline in Parenteral Nutrition Intravenous (PN/IV) Caloric Intake at Week 24 [ Time Frame: Baseline, Week 24 ]
    Change in PN/IV caloric intake was reported based on the participant diary and the investigator prescribed data.

  5. Change From Baseline in Plasma Citrulline Levels at Week 24 [ Time Frame: Baseline, Week 24 ]
    Plasma citrulline level was reported.

  6. Change From Baseline in Enteral Nutrition Volume at Week 24 [ Time Frame: Baseline, Week 24 ]
    Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition volume was reported.

  7. Change From Baseline in Enteral Nutrition Caloric Intake at Week 24 [ Time Frame: Baseline, Week 24 ]
    Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition caloric intake was reported.

  8. Change From Week 24 in Parenteral Nutrition Intravenous (PN/IV) Volume at Week 28 [ Time Frame: Week 24, Week 28 ]
    Change in PN/IV volume was reported.

  9. Change From Week 24 in Parenteral Nutrition Intravenous (PN/IV) Caloric Intake at Week 28 [ Time Frame: Week 24, Week 28 ]
    Change in PN/IV caloric intake was reported.

  10. Change From Week 24 in Plasma Citrulline Levels at Week 28 [ Time Frame: Week 24, Week 28 ]
    Change in plasma citrulline level was reported.

  11. Change From Week 24 in Enteral Nutrition Volume at Week 28 [ Time Frame: Week 24, Week 28 ]
    Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition volume was reported.

  12. Change From Week 24 in Enteral Nutrition Caloric Intake at Week 28 [ Time Frame: Week 24, Week 28 ]
    Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition caloric intake was reported.

  13. Change From Baseline in Body Weight Z-score at Week 28 [ Time Frame: Baseline, Week 28 ]
    Body weight z-score is a measure of relative weight adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.

  14. Change From Baseline in Body Height Z-score at Week 28 [ Time Frame: Baseline, Week 28 ]
    Body height z-score is a measure of relative height adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.

  15. Change From Baseline in Head Circumference Z-score at Week 28 [ Time Frame: Baseline, Week 28 ]
    Head circumference z-score is a measure of relative head circumference adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean. Head circumference was collected only for participants of less than or equal to (<=) 36 months of age at the time of measurement.

  16. Change From Baseline in Body Mass Index (BMI) Z-score at Week 28 [ Time Frame: Baseline, Week 28 ]
    BMI z-score is a measure of relative BMI adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.

  17. Change From Baseline in Participants' Stool Consistency at Week 28 [ Time Frame: Baseline, Week 28 ]
    Stool consistency was assessed by typical stool form based on Bristol Stool Form Scale: 1 - Separate hard lumps, hard to pass, 2 - Sausage-shaped, but lumpy, 3 - Like a sausage but with cracks on the surface, 4 - Like a sausage or snake, smooth and soft, 5 - Soft blobs with clear-cut edges, 6 - Fluffy pieces with ragged edges, a mushy stool, 7 - Watery, no solid pieces, entirely liquid.

  18. Change From Baseline in Hours Per Day of Parenteral Nutrition Intravenous (PN/IV) Support at Week 24 [ Time Frame: Baseline, Week 24 ]
    The mean duration of the PN/IV infusions in hours, on the days when PN/IV was administered was reported.

  19. Change From Baseline in Days Per Week of Parenteral Nutrition Intravenous (PN/IV) Support at Week 24 [ Time Frame: Baseline, Week 24 ]
    The number of days per week of PN/IV infusions were reported.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Informed consent by a parent or guardian or emancipated minor prior to any study-related procedures
  2. When applicable, an informed assent by the subject (as deemed appropriate by the Ethics Committee/Institutional Review Board) prior to any study-related procedures
  3. Current history of SBS as a result of major intestinal resection, (eg, due to necrotizing enterocolitis, midgut volvulus, intestinal atresia, or gastroschisis)
  4. Short bowel syndrome that requires PN/IV support that provides at least 30% of caloric and/or fluid/electrolyte needs prior to screening
  5. Stable PN/IV support, defined as inability to significantly reduce PN/IV support, usually associated with minimal or no advance in enteral feeds (ie, 10% or less change in PN or advance in feeds) for at least 3 months prior to and during screening, as assessed by the investigator.
  6. Sexually active female subjects of child-bearing potential (in the teduglutide treatment arm only) must use medically acceptable methods of birth control during and 4 weeks after the treatment period

Exclusion Criteria:

  1. Subjects who are not expected to be able to advance oral or tube feeding regimens
  2. Serial transverse enteroplasty or any other bowel lengthening procedure performed within 3 months of screening
  3. Known clinically significant untreated intestinal obstruction contributing to feeding intolerance and inability to reduce parenteral support
  4. Unstable absorption due to cystic fibrosis or known DNA abnormalities
  5. Severe, known dysmotility syndrome, such as pseudo-obstruction or persistent, severe, active gastroschisis-related dysmotility, that is the primary contributing factor to feeding intolerance and inability to reduce parenteral support, prior to screening. Dysmotility is defined as severe if it is expected to limit the advancement of enteral feeding.
  6. Evidence of clinically significant obstruction on upper GI series done within 6 months prior to screening.
  7. Major GI surgical intervention including significant intestinal resection within 3 months prior to the screening visit (insertion of feeding tube, anastomotic ulcer repair, minor intestinal resections ≤ 10 cm, or endoscopic procedure is allowed).
  8. Unstable cardiac disease, congenital heart disease or cyanotic disease, with the exception of subjects who had undergone ventricular or atrial septal defect repair, and patent ductus arteriosus (PDA) ligation.
  9. History of cancer or clinically significant lymphoproliferative disease, not including resected cutaneous basal or squamous cell carcinoma, or in situ non aggressive and surgically resected cancer.
  10. Pregnant or lactating female subjects (in the teduglutide treatment arm only).
  11. Participation in a clinical study using an experimental drug (other than glutamine or Omegaven) within 3 months or 5.5 half-lives of the experimental drug, whichever is longer, prior to screening, and for the duration of the study.
  12. Previous use of teduglutide or native/synthetic glucagon-like peptide-2 (GLP-2)
  13. Previous use of glucagon-like peptide-1 analog or human growth hormone within 3 months prior to screening
  14. Previous use of octreotide, or dipeptidyl peptidase-4 (DPP-4) inhibitors within 3 months prior to screening
  15. Subjects with active Crohn's disease who had been treated with biological therapy (eg, antitumor necrosis factor [anti-TNF]) within the 6 months prior to the screening visit
  16. Subjects with inflammatory bowel disease (IBD) who require chronic systemic immunosuppressant therapy that had been introduced or changed during the 3 months prior to screening
  17. More than 3 SBS-related or PN-related hospital admissions (eg, documented infection-related catheter sepsis, clots, bowel obstruction, severe water-electrolyte disturbances) within 3 months prior to the screening visit
  18. Any major unscheduled hospital admission which affects parenteral support requirements within 1 month prior to or during screening, excluding uncomplicated treatment of bacteremia, central line replacement/repair, or issues of similar magnitude in an otherwise stable subject
  19. Body weight < 10 kg at the screening and baseline visits
  20. Signs of active severe or unstable, clinically significant hepatic impairment during the screening period, as indicated by any of the following laboratory test results :

    1. Total bilirubin (TBL) ≥ 2 x upper limit of normal (ULN)
    2. Aspartate aminotransferase (AST) ≥ 7x ULN
    3. Alanine aminotransferase (ALT) ≥ 7x ULN

      For subjects with Gilbert's disease:

    4. Indirect (unconjugated) bilirubin ≥ 2x ULN
  21. Signs of known continuous active or unstable, clinically significant renal dysfunction shown by results of an estimated glomerular filtration rate (eGFR) below 50 mL/min/1.73 m2.
  22. Parent(s) and/or subjects who are not capable of understanding or not willing to adhere to the study visit schedule and other protocol requirements
  23. Unstable, clinically significant active, untreated pancreatic or biliary disease
  24. Any condition, disease, illness, or circumstance that in the investigator's opinion puts the subject at any undue risk, prevents completion of the study, or interferes with analysis of the study results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02682381


  Hide Study Locations
Locations
Layout table for location information
United States, California
Children's Hospital Los Angeles - RHU
Los Angeles, California, United States, 90027
UCLA Dept. of Medicine
Los Angeles, California, United States, 90095
UCSF Benioff Children's Hospital
San Francisco, California, United States, 94158
United States, District of Columbia
Georgetown Children's Research Network
Washington, District of Columbia, United States, 20007
United States, Illinois
Ann & Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611
United States, Indiana
Riley Hospital for Children
Indianapolis, Indiana, United States, 46202
United States, Massachusetts
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
United States, Nebraska
The Nebraska Medical Center
Omaha, Nebraska, United States, 68198
United States, New York
Montefiore Medical Center Child Spc
Bronx, New York, United States, 10467
Children's Hospital GI Nutrition
New York, New York, United States, 10032
United States, North Carolina
Duke Medical Center
Durham, North Carolina, United States, 27710
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
Cleveland Clinic Pediatric Specialists
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
Children's Medical Center Dallas
Dallas, Texas, United States, 75235
Texas Children's Hospital
Houston, Texas, United States, 77030
United States, Washington
Seattle Children's Hospital
Seattle, Washington, United States, 98105
United States, Wisconsin
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, United States, 53792
Belgium
Cliniques Universitaires Saint-Luc
Bruxelles, Belgium, 1200
Canada, Alberta
Walter C. Mackenzie Health Science Center
Edmonton, Alberta, Canada, T6G 1C9
Canada, British Columbia
British Columbia Children's & Women's Hospital Center
Vancouver, British Columbia, Canada, V6H 3V4
Canada, Ontario
The Hospital for Sick Children
Toronto, Ontario, Canada, M5G 1X8
Finland
Helsingin yliopistollinen keskussairaala
Helsinki, Finland, 00290
Germany
Universitaetsklinikum Tuebingen
Tuebingen, Baden Wuertternberg, Germany, 72076
Italy
Ospedale Pediatrico Bambino Gesu
Roma, Italy, 00165
United Kingdom
Great Ormond Street Hospital for Children
London, Greater London, United Kingdom, WC1N 3JH
Birmingham Children's Hospital
Birmingham, United Kingdom, B4 6NH
Sponsors and Collaborators
Shire
Investigators
Layout table for investigator information
Study Director: Shire Physician Shire
  Study Documents (Full-Text)

Documents provided by Shire:
Study Protocol: Protocol  [PDF] March 12, 2015
Study Protocol: Amendment1  [PDF] June 22, 2015
Study Protocol: Amendment3  [PDF] February 25, 2016
Study Protocol: Amendment4  [PDF] March 15, 2016
Statistical Analysis Plan  [PDF] July 14, 2017
Study Protocol: Amendment2  [PDF] October 6, 2015


Layout table for additonal information
Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT02682381     History of Changes
Other Study ID Numbers: TED-C14-006
First Posted: February 15, 2016    Key Record Dates
Results First Posted: October 16, 2018
Last Update Posted: May 16, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Access Criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
URL: https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers
Keywords provided by Shire:
Teduglutide
pediatric
GLP-2
parenteral support
Short Bowel Syndrome
short gut syndrome
short gut
SBS
parenteral nutrition
Additional relevant MeSH terms:
Layout table for MeSH terms
Teduglutide
Short Bowel Syndrome
Syndrome
Disease
Pathologic Processes
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Postoperative Complications
Gastrointestinal Agents
Radiation-Protective Agents
Protective Agents
Physiological Effects of Drugs